Drug Approval | March 23, 2022
Covovax for teens get DCGI nod
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
Data to establish the safety profile and human dose of vaccine candidate
Arum's research focuses on the discovery of new chemical entities that will act as effective therapies for drug-resistant cancers
Voluntary nationwide recall of lots of Accuretic (quinapril HCl/hydrochlorothiazide), quinapril and hydrochlorothiazide tablets, and quinapril HCl/hydrochlorothiazide tablets due to n-nitroso- quinapril content
Christian brings a unique level of experience and expertise from a 20-year career at BASF across multiple territories and businesses
The investment will improve equipment efficiency and increase safety standards at its Lestrem site
The expansion makes Exothera one of the largest viral vector facilities in Europe
New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease
Twelve abstracts and two late-breaking presentations demonstrate AbbVie and Allergan Aesthetics' shared commitment to advancing research across a spectrum of dermatologic conditions and aesthetic indications
Milltrust Ventures will also assist Oncoshot with its expansion in Australia and India, where the latter has already established partnerships amongst apex cancer institutes
Subscribe To Our Newsletter & Stay Updated
